The impact of therapy on quality of life and mood in neuropathic pain: What is the effect of pain reduction?

Anesthesia and Analgesia

Volumn 102, Issue 5, 2006, Pages 1473-1479

  Deshpande, Maneesh A ^a   Holden, Ronald R ^a   Gilron, Ian ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN; MORPHINE;

ADULT; ANALGESIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG EFFECT; EFFECT SIZE; EVALUATION; FEMALE; HUMAN; MALE; MOOD; NEUROPATHIC PAIN; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PRIORITY JOURNAL; PROFILE OF MOOD STATES; QUALITY OF LIFE; SCORING SYSTEM; SEDATION; SHORT FORM 36; SIDE EFFECT; XEROSTOMIA;

EID: 33646198397     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ane.0000204295.90178.77     Document Type: Article

References (33)

1. Scadding JW. Peripheral neuropathies. In: Wall PD, Melzack R, eds. Textbook of pain, 3rd ed. Edinburgh: Churchill Livingstone, 1994, 667-83.
2. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002;18:350-4.
3. Penny KI, Purves AM, Smith BH, et al. Relationship between the chronic pain grade and measures of physical, social and psychological well-being. Pain 1999;79:275-9.
4. Haythornthwaite JA, Benrud-Larson LM. Psychological assessment and treatment of patients with neuropathic pain. Curr Pain Headache Rep 2001;5:124-9.
5. Turk DC, Dworkin RH, Allen RR, et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain 2003;106:337-45.
6. Cruccu G, Anand P, Attal N, et al. EFNS guidelines on neuropathic pain assessment. Eur J Neurol 2004;11:153-62.
7. McQuay HJ, Tramer M, Nye BA, et al. A systematic review of antidepressants in neuropathic pain. Pain 1996;68:217-27.
8. Collins SL, Moore RA, McQuay HJ, Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage 2000;20:449-58.
9. Watson CP. The treatment of neuropathic pain: antidepressants and opioids. Clin J Pain 2000;16:S49-55.
10. McQuay HJ, Carroll D, Jadad AR, et al. Dextromethorphan for the treatment of neuropathic pain: a double-blind randomised controlled crossover trial with integral n-of-1 design. Pain 1994;59:127-33.
11. McCleane G. 200 mg daily of lamotrigine has no analgesic effect in neuropathic pain: a randomised, double-blind, placebo controlled trial. Pain 1999;83:105-7.
12. Wallace MS, Magnuson S, Ridgeway B. Efficacy of oral mexiletine for neuropathic pain with allodynia: a double-blind, placebo-controlled, crossover study. Reg Anesth Pain Med 2000;25:459-67.
13. Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987;37:589-96.
14. Kishore-Kumar R, Max MB, Schafer SC, et al. Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther 1990;47:305-12.
15. Kalso E, Tasmuth T, Neuvonen PJ. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain 1996;64:293-302.
16. Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998;50:1837-41.
17. Bone M, Critchley P, Buggy DJ. Gabapentin in postamputation phantom limb pain: a randomized, double-blind, placebo-controlled, cross-over study. Reg Anesth Pain Med 2002;27:481-6.
18. Boureau F, Legallicier P, Kabir-Ahmadi M. Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain 2003;104:323-31.
19. Turner JA, Deyo RA, Loeser JD, et al. The importance of placebo effects in pain treatment and research. JAMA 1994;271:1609-14.
20. Sator-Katzenschlager SM, Schiesser AW, Kozek-Langenecker SA, et al. Does pain relief improve pain behavior and mood in chronic pain patients? Anesth Analg 2003;97:791-7.
21. Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352:1324-34.
22. Melzack R. The short-form McGill Pain Questionnaire. Pain 1987;30:191-7.
23. Ware JE, Snow KK, Kosinski MA, Gandek MS. SF-36 Health Survey manual and interpretation guide. Boston: Nimrod Press, 1997.
24. McNair DM, Lorr M, Droppleman LP. EdITS manual for the profile of mood states, educational and industrial testing service, San Diego: EdITS, 1992.
25. Soderman P, Malchau H. Is the Harris hip score system useful to study the outcome of total hip replacement? Clin Orthop 2001;384:189-97.
26. Hopman WM, Towheed T, Anastassiades T, et al. Can normative data for the SF-36 health survey. Can Multicentre Osteoporosis Study Research Group, CMAJ 2000;163:265-71.
27. Cohen J. A power primer. Psychol Bull 1992;112:155-9.
28. Katz N. The impact of pain management on quality of life. J Pain Symptom Manage. 2002;24(1 Suppl):S38-47.
29. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9-19.
30. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998;280:1831-6.
31. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998;280:1837-42.
32. Serpell MG. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain 2002;99:557-66.
33. Aparasu R, McCoy RA, Weber C, et al. Opioid-induced emesis among hospitalized nonsurgical patients: effect on pain and quality of life. J Pain Symptom Manage 1999;18:280-8.